Novavax INC 10-Q quarterly reports

Novavax, Inc. announced its second quarter 2026 financial results, reporting a substantial decrease in total revenue and a net loss, primarily driven by lower product sales and licensing income.

Novavax reported a significant revenue decline in Q1 2026, primarily due to lower product sales, but saw a substantial increase in licensing, royalties, and other income, driven by new partnerships and amortization of upfront payments.

Novavax reports a significant increase in nine-month revenue driven by APA terminations and Sanofi collaboration milestones, alongside a Q3 net loss and strategic debt refinancing.

Novavax reported a significant net income increase for the first half of 2025 driven by contract terminations, despite a Q2 revenue decline, as it advances key partnerships and pipeline assets.

Novavax reports a significant turnaround in Q1 2025, posting a net income of $518.6 million, primarily due to revenue from collaboration agreements and termination of Advance Purchase Agreements (APAs).

Novavax's Q3 2024 results show a decrease in revenue primarily due to reduced government grants, offset by increased product sales and licensing revenue from the Sanofi partnership.

Novavax's Q2 2024 results show a significant increase in revenue driven by a licensing agreement with Sanofi, alongside a reduction in operating expenses.

Novavax's Q1 2024 results show a net loss of $147.6 million, but the company has secured a major collaboration with Sanofi, providing a $500 million upfront payment and a $68.8 million equity investment.